Journal of Alzheimer's Disease

Journal of Alzheimer's Disease An international multidisciplinary journal The journal publishes research reports, reviews, short communications, book reviews, and letters-to-the-editor.

JAD is an international multidisciplinary journal to facilitate progress in understanding the etiology, pathogenesis, epidemiology, genetics, behavior, treatment and psychology of Alzheimer’s disease. The journal is dedicated to providing an open forum for original research that will expedite our fundamental understanding of Alzheimer’s disease. Editor-in-Chief
George Perry, PhD
University of Texa

s at San Antonio
USA
Tel: +1.210.458.8660
Fax:+1.210.458.5658
Email: [email protected]
ORCID iD: 0000-0002-6547-0172

To view the full list of the Editorial Board, please visit: http://j-alz.com/board. JAD is a member of the Neuroscience Peer Review Consortium (http://nprc.incf.org). The Consortium is an alliance of neuroscience journals that have agreed to accept manuscript reviews from each other. Abstracting/Indexing

Biological Abstracts
BIOSIS Previews
CAB Abstracts
CAB Health
Chemical Abstracts Service (CAS)
CSA Biological Sciences
CSA Illumina
CSA Illustrata Natural Sciences
CSA Neurosciences Abstracts
e-psyche database
EBSCO database
Embase
EMCare
Index Copernicus
Index Medicus
Journal Citation Reports/Science Edition
MEDLINE
Neuroscience Citation Index
Prous Science Integrity
PsycInfo
PubMed
PubsHub
Science Citation Index Expanded (SciSearch)
Scopus

Audience

JAD's targeted audience is comprised of basic science researchers and clinicians in the areas of Alzheimer's disease and related disorders.

07/08/2026

News and commentary from the world of neurology and neuroscience

07/08/2026

New study reflects competing risks that shape aging trajectories

07/08/2026

Emerging evidence suggests that while short-form videos may engage learners, they may also disrupt attention, memory, and brain networks essential for effective learning.

07/08/2026

Study reveals new role for tau, a top target for Alzheimer’s drug development
Stanford scientists pursue mechanism driving protein’s effect on cells in neurodegeneration

With Rush University System for Health – I just got recognized as one of their top fans! 🎉
06/08/2026

With Rush University System for Health – I just got recognized as one of their top fans! 🎉

06/08/2026

Sign in or join now to see posts like this one and more.

06/08/2026

As Immunotherapy Use Grows, U.S. Clinics Innovate to Handle the Load Go to another part Series - Alzheimer's Association International Conference® - AAIC 2026: Quick Links Article Comments References Further Reading Tools Add to my Library Follow News Comments Share How would you like to share? Fac...

06/08/2026

In China and U.S. Real-World Use, Leqembi Seems to Stabilize Cognition Go to another part Series - Alzheimer's Association International Conference® - AAIC 2026: Quick Links Article Comments References Further Reading Tools Add to my Library Follow News Comments Share How would you like to share? F...

06/08/2026

De-Risking Donanemab: Dosing Tweak Cuts ARIA; Steroids, Not so Much Go to another part Series - Alzheimer's Association International Conference® - AAIC 2026: Quick Links Article Comments References Further Reading Tools Add to my Library Follow News Comments Share How would you like to share? Face...

06/08/2026

Scientists Chart Tau Modifications as Alzheimer’s Advances Go to another part Series - Alzheimer's Association International Conference® - AAIC 2026: Quick Links Article Comments References Further Reading Tools Add to my Library Follow Comments Share How would you like to share? Facebook X Linke...

Adres

Nieuwe Hemweg 6B
Amsterdam
1013BG

Meldingen

Wees de eerste die het weet en laat ons u een e-mail sturen wanneer Journal of Alzheimer's Disease nieuws en promoties plaatst. Uw e-mailadres wordt niet voor andere doeleinden gebruikt en u kunt zich op elk gewenst moment afmelden.

Contact De Praktijk

Stuur een bericht naar Journal of Alzheimer's Disease:

Snelkoppelingen

Uitgelicht

Delen